Late relapse of IgM nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma

ICPIs were effective for primary and metastatic foci of lung adenocarcinoma, but their repeated use provoked a late relapse of IgM nephropathy and lethal lesions in pancreas and lung. ICPIs should be used carefully in cases of immune‐related disease.

Detalles Bibliográficos
Autores principales: Odani, Kentaro, Tachibana, Mitsuhiro, Nogaki, Fumiaki, Tsutsumi, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077308/
https://www.ncbi.nlm.nih.gov/pubmed/33936615
http://dx.doi.org/10.1002/ccr3.3903
_version_ 1783684857005604864
author Odani, Kentaro
Tachibana, Mitsuhiro
Nogaki, Fumiaki
Tsutsumi, Yutaka
author_facet Odani, Kentaro
Tachibana, Mitsuhiro
Nogaki, Fumiaki
Tsutsumi, Yutaka
author_sort Odani, Kentaro
collection PubMed
description ICPIs were effective for primary and metastatic foci of lung adenocarcinoma, but their repeated use provoked a late relapse of IgM nephropathy and lethal lesions in pancreas and lung. ICPIs should be used carefully in cases of immune‐related disease.
format Online
Article
Text
id pubmed-8077308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80773082021-04-29 Late relapse of IgM nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma Odani, Kentaro Tachibana, Mitsuhiro Nogaki, Fumiaki Tsutsumi, Yutaka Clin Case Rep Case Reports ICPIs were effective for primary and metastatic foci of lung adenocarcinoma, but their repeated use provoked a late relapse of IgM nephropathy and lethal lesions in pancreas and lung. ICPIs should be used carefully in cases of immune‐related disease. John Wiley and Sons Inc. 2021-03-02 /pmc/articles/PMC8077308/ /pubmed/33936615 http://dx.doi.org/10.1002/ccr3.3903 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Odani, Kentaro
Tachibana, Mitsuhiro
Nogaki, Fumiaki
Tsutsumi, Yutaka
Late relapse of IgM nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma
title Late relapse of IgM nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma
title_full Late relapse of IgM nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma
title_fullStr Late relapse of IgM nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma
title_full_unstemmed Late relapse of IgM nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma
title_short Late relapse of IgM nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma
title_sort late relapse of igm nephropathy‐associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077308/
https://www.ncbi.nlm.nih.gov/pubmed/33936615
http://dx.doi.org/10.1002/ccr3.3903
work_keys_str_mv AT odanikentaro laterelapseofigmnephropathyassociatednephroticsyndromeafterrepeatedadministrationofimmunecheckpointinhibitoragainstpulmonaryadenocarcinoma
AT tachibanamitsuhiro laterelapseofigmnephropathyassociatednephroticsyndromeafterrepeatedadministrationofimmunecheckpointinhibitoragainstpulmonaryadenocarcinoma
AT nogakifumiaki laterelapseofigmnephropathyassociatednephroticsyndromeafterrepeatedadministrationofimmunecheckpointinhibitoragainstpulmonaryadenocarcinoma
AT tsutsumiyutaka laterelapseofigmnephropathyassociatednephroticsyndromeafterrepeatedadministrationofimmunecheckpointinhibitoragainstpulmonaryadenocarcinoma

Ejemplares similares